Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

<p>Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation d...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Aasir M. Suliman (14150217) (author)
مؤلفون آخرون: Shaza A. Bek (14150220) (author), Mohamed S. Elkhatim (14150223) (author), Ahmed A. Husain (11819156) (author), Ahmad Y. Mismar (14150226) (author), M. Z. Sharaf Eldean (14150229) (author), Zsolt Lengyel (3427871) (author), Shereen Elazzazy (9545774) (author), Kakil I. Rasul (14150232) (author), Nabil E. Omar (9545756) (author)
منشور في: 2022
الموضوعات:
Oncology and carcinogenesis
Cancer Research
Oncology
Immunology
Immunology and Allergy
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

مواد مشابهة